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Abstract
Introduction Cancer may affect the central nervous system
either by primary or secondary brain tumours (PBT/SBT).
Specific needs of these patients and special requirements of
services caring for them have not been adequately
addressed so far.
Methods Since 1999, an annual, 3-month census is being
conducted in different palliative care settings throughout
Germany. Pooled data from the years 2002–2005 were
analysed to test for differences between patients with PBT,
SBT and other palliative care patients (OP). Symptom
frequencies, ECOG status and nursing needs were tested for
differences (χ²). Free text entries for reasons for admission
were recorded, categorised and analysed descriptively.
Results A total of 5,684 patients were documented (PBT n=
153, 2.7%; SBT n=661, 11.9%; OP n=4,872, 85.4%). For
patients with PBT, poor functional status and high need
for nursing support was reported more frequently than for
patients with SBT and OP. For patients with PBT/SBT
physical symptoms (pain, nausea, vomiting, constipation and
loss of appetite) were documented less frequently and in
lower intensity than for OP. However, nursing, psycholog-
ical, and social problems/symptoms were documented
significantly more often and showed higher intensity,
particularly the patients'’ need for support with the activities
of daily living, disorientation/confusion of the patients and
overburdening of the family. For 67% of all patients, a
reason for admission was documented in free text. Main
reasons were symptom control (OP>SBT>PBT), social
issues (PBT>SBT>OP), functional deficits (PBT>SBT>OP)
and cognitive impairment (PBT/SBT>OP). Distinct neuro-
logical deficits and problems were documented more often
as secondary ICD-diagnoses than as a leading reason for
admission.
Conclusion The specific palliative care problems and the
rationales leading to health care utilisation point to the need
for an appropriate interdisciplinary and multi-professional
provision of care for patients with brain malignancies, with
a particular view on the needs of the families and an early
integration of social and psychological support.
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Involvement of the central nervous system is common in
patients with cancer. Secondary brain tumours develop in 20–
40% of systemic malignancies at some point during the illness
[1]. Brain metastases significantly reduce life expectancy,
with a mean survival of 1–6 months, depending on histology
and applied therapies [2]. Primary brain tumours belong to
the rarer neoplasms with less than 2% of the newly diagnosed
cancers [3]. One fourth to one third of these are highly
malignant gliomas with a median survival of 5–10 months [4,
5]. Primary or secondary brain tumours often lead to serious
deterioration of neurological and cognitive functions [6].
Besides the existential distress, patients and their families
suffer from fears that this condition may lead to a change or
loss of individual control, cognition or consciousness, as well
as the patients' personality.
Palliative care addresses symptoms and problems caused
by progressive, life-limiting diseases irrespective of the
underlying diagnosis [7]. Due to restricted options to limit
the progression of the disease for the majority of patients
with primary brain tumours, especially glioblastoma, or
brain metastases, the management has to focus on the best
possible palliation. To meet the specific needs of these
patients appropriately, a more detailed evaluation of this
specific group is required. Only little information on this
topic is available [8, 9], and it is neither known whether
there are differences in the palliative care needs of patients
with primary and secondary brain tumours nor whether
differences to other palliative care patient groups exist.
In this study, we analysed prospectively collected core data
sets of palliative care patients (1) to detect possible variations
inpalliativecareproblemsinpatientswithmalignanciesinthe
central nervous system compared with other patients in
palliative care and (2) to determine what the essential issues
for services caring for this particular patient group are.
Methods
Since 1996, a standardised basic documentation tool
(Hospice and Palliative care Evaluation (HOPE)) for
palliative care patients has been developed, evaluated and
amended accordingly by a multi-professional working
group. Each year, German inpatient and outpatient hospice
and palliative care services (Table 1) are recruited to
participate in a 3-month census. The participants document
up to 30 consecutive palliative care patients at admission to
the service and at the time of discharge or death. The
anonymised data can be submitted via use of an online
database or a two-page paper questionnaire and is pro-
cessed centrally.
For this study, data on age, gender, diagnosis, metasta-
ses, concomitant diseases, functional status, prevalence and
intensity of symptoms as well as psychological, nursing and
social problems were pooled (years 2002, 2004 and 2005
1)
and analysed. Symptoms and problems were assessed by
staff via an integrated symptom checklist (Table 2) using a
4-point grading scale (0 = none, 1 = mild, 2 = moderate,
3 = severe). This symptom checklist was constructed as part
of the documentation tool for a general palliative care
population, serving to document a patient's status and not to
reflect specific diagnoses (for example “feeling depressed”
and not “depression”). Detailed information on the devel-
opment of the documentation tool has been published
previously [10, 11]. HOPE was used in several epidemio-
logical surveys in Germany [10, 12–14]. Further evaluation
of the psychometric properties is currently being performed.
Patients with primary brain tumours were identified by
the documented ICD10 Code and/or free text entries for the
main diagnosis. Patients with secondary brain tumours
could be identified as the core documentation included an
item on the site of metastases. Differences between patients
with primary and secondary brain tumours as well as
between both groups and other patients without malignant
affection of the central nervous system were analysed.
Comparative analysis was performed for place of care,
performance status according to the Eastern Cooperative
1 Due to the fact that data analysis, feedback to the institutions and
discussion about modification of the instrument lasted 15 months on
average, no census was performed in 2003. Since 2005, the census has
been repeated annually, as the infrastructure is now optimised and the
instrument can be used as a standard documentation tool.
Year 2002 2004 2005 Number of patients
Palliative care units 54 68 53 4,182
Hospices 9 12 12 653
General practitioners – 7 8 342
Oncological units 5 3 6 281
Home care – 4 5 177
Geriatric units 2 –– 49
Documented pts 1,567 2,214 1,903 5,684
Table 1 Number of
participating units and
documented patients
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for documented symptoms and problems. The nursing
levels
2 were graded according to the German legislation
on long-term care in four different levels depending on
type, frequency and duration of the need for nursing [16]
(Table 3).
The programme packet SPSS 14.0 (SPSS Inc, Chicago, IL,
USA) was used for statistical evaluation. Prevalence of
symptoms and problems with higher intensity (moderate and
severe) at the time of admission was determined. Group
differences for these symptoms/problems, as well as for gender,
placeofcare,levelsofnursingcare,ECOGweretestedwithchi-
square, differences in age and length of stay and with ANOVA.
For statistical significance we used p< 0 . 0 5i na l lt e s t s .
The core data set includes free text entries for the reason
for admission. These free text entries were recorded (e.g.
pain, pain management, adaptation of analgesic regimen
were coded as a subcategory pain) and categorised (e.g.
pain and other symptoms were aggregated to a main
category symptom management). As the instrument was
not developed specifically for patients with brain malig-
nancies, free text entries on reasons for admission were
additionally scanned for specific neurological problems.
This data was compared with neurological diagnoses
documented as ICD-10 codes (seizures: G40–41; paresis:
G8 1 –83/G 53.3; brain oedema: G93.6) to determine
whether specific neurological problems were considered to
be a reason for admission to palliative care. This data was
evaluated descriptively only, as not for all patients a reason
for admission was documented.
Results
A total of 5,684 palliative care patients were documented in
the period under review. More than 50% of the German
palliative care units (2002, 79 units; 2004, 106; 2005,116)
[13, 17] participated. The number of participating hospices
3,
general practitioners, oncology wards, home care services
and geriatric wards was considerably lower (Table 1).
A primary brain tumour (PBT) was the main diagnosis in
151 patients (2.6%); 661 patients (11.9%) with other primary
cancers had brain metastases (secondary brain tumours
(SBT)) at the time of admission. The most common sites of
the primary were lung (38.7%), breast (19.5%) and gastro-
intestinal tract (11.3%). No gender differences were detect-
able. Patients suffering from malignancies of the brain were
significantly younger than other patients (PBT, 62.8 years±
14.8; SBT, 63.2 years±12.3; other palliative care patients
(OP), 68.4 years±12.3; PBT/SBT, n.s.; PBT/OP, F 29.1 p<
0.001; SBT/OP, F 42.4 p<0.001).
Differential palliative care issues
Functional status (ECOG) and need for nursing differed
significantly. Patients with PBT and SBT showed more
frequently a poor functional status (ECOG 3–4) compared
with OP (Table 4). A high need for nursing support
(level III) was documented more often for patients with
PBT than for OP and patients with SBT (Table 4). The
length of stay until discharge or death was significantly
longer (F 4.5; p=0.035) in patients with PBT (16.8 days±
16.1) compared with OP (14.3 days±14.3), but not in
comparison with patients with SBT (14.5 days±13.4). In
the period under review, significantly more patients with
SBT died than OP or patients with PBT (Table 4).
The analysis of symptom/problem prevalences and
intensities as documented in the symptom and problem
checklist also showed significant differences. Most physical
symptoms (except for weakness, tiredness and dyspnea)
were documented less often with moderate to severe
intensity in patients with PBT/SBT compared with OP
(Table 5). Need for support in the activities of daily living,
symptoms of disorientation/confusion and problems with
overburdening of the family were documented more often
for patients with SBT and PBT (Table 5). Emotional strain
and anxiety were more prevalent in patients with SBT
compared with OP and patients with PBT (Table 5).
Reason for admission
In 67% (n=3,810) of all patients, a reason for admission
was documented in free text. Here, mainly symptom control
(PBT, 39.2%; SBT, 57.4%; OP 69,4%), social issues (PBT,
27.8%; SBT, 18.9%; OP, 15.8%), functional deficits (PBT,
3 In Germany, palliative care units are medical units, integrated into
hospitals and have an average stay of 9 days. Hospices focus on
nursing needs, are freestanding, generally patients remain there until
they die. Funding for services also differs.
Physical Pain, nausea, vomiting, dyspnoea, constipation, weakness, loss of appetite, tiredness
Nursing Wound care, activities of daily living
Psychological Feeling depressed, anxiety, emotional strain, disorientation/confusion
Social Need for social support, overburden of family
Table 2 Symptoms and
problems assessed with Hospice
and Palliative care Evaluation
(HOPE)
2 According to the German long-term care legislation patients have to
apply for a nursing level in order to receive financial aids. The
grouping to a certain level implies a dedicated need for nursing
support (higher level = higher need for nursing support (Table 3)) and
aligns for a certain financial grant.
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(PBT, 10.3%; SBT, 10.5%; OP, 3.5%) were documented
(Table 6). Distinct neurological deficits and problems were
documented more often as secondary ICD-diagnoses than
as a leading reason for admission (Table 6).
Discussion
Due to the lack of curative treatment options for many
patients with primary brain tumours and their reduced life
expectancy, good palliative care is essential [18]. For
patients with cancer of other origin, the diagnosis of
secondary brain tumours frequently determines the transi-
tion from a curative to a palliative situation [19]. Yet to
date, there has been no systematic evaluation and compar-
ison of specific palliative care problems and needs of
patients with central nervous neoplasms within a palliative
care population based on a broad, prospectively collected
data pool.
The study presented here shows that symptoms and
problems in patients with primary brain tumours differ
significantly in prevalence and intensity from those of other
palliative care patients. Patients with primary brain tumours
had evidence of more advanced disease such as poorer
performance status and higher levels of nursing support.
However, physical symptoms, except weakness and tired-
ness, were documented less frequently and with lower
intensity. Nursing problems and psychological problems
showed little differences except for a predominance of
disorientation and confusion in patients with primary brain
tumours. The need for social support and overburdening of
the family were significantly more often documented in
patients with primary brain tumours.
Table 4 Comparison of characteristics (places of care, levels of nursing care and functional status) between the patients with primary brain
tumours, secondary brain tumours and the other patients without malignant brain disease
Group differences
Group Primary brain
tumour (PBT)
N=151
Secondary
brain tumour
(SBT) N=661
Other patients
(OP) N=4,872
PBT/SBT PBT/OP SBT/OP
Item
N % N % N %
Place of care
Palliative care unit 103 68.2 480 72.6 3,599 73.9
Hospice 30 19.9 102 15.4 521 10.7 p<0.001 (χ² 12.6) p<0.001 (χ² 13.1)
General practitioner 15 9.9 34 5.1 293 6 p=0.026 (χ² 5.0) p=0.048 (χ² 3.9)
Oncology –– 15 2.3 266 5.5 p<0.001 (χ² 12.3)
Home care 3 2 30 4.5 144 3 p=0.029 (χ² 4.8)
Geriatrics –– –– 49 1
Nursing levels
None 35 23.2 224 33.9 2,096 43 p=0.011 (χ² 6.5) p<0.001 (χ² 23.6) p<0.001 (χ² 19.9)
Applied for 35 23.2 148 22.4 854 17.5 p=0.002 (χ² 9.3)
Level I 19 12.6 87 13.2 607 12.5
Level II 21 13.9 82 12.4 509 10.4
Level III 18 11.9 23 3.5 147 3.0 p<0.001 (χ² 18.3) p<0.001 (χ² 36.5)
Level III+ –– 1 0.2 23 0.5
ECOG 3 or 4 128 90.1 534 84.5 3,289 71.7 p<0.001 (χ² 23.3) p<0.001 (χ² 46.3)
Death 62 44.0 349 55.2 2,176 47.3 p=0.015 (χ² 5.9) p<0.001 (χ² 13.9)
Table 3 Nursing levels according to the German long-term care legislation [16]
Level I Support is necessary for at least two activities in the areas of personal hygiene, nutrition and mobility (at least once a day)
as well as housekeeping (at least several times a week) with an overall average duration of at least 90 min/day
Level II Support is necessary at least three times a day with an overall average duration of at least 3 h/day
Level III Support is necessary around the clock including nights with an overall average duration of at least 5 h/day
Level III+ Cases of hardship with exceptionally high need for support
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related to underrecognition and underassessment in those
patients. This could be due to the difficult symptom
assessment in cognitively impaired patients. In addition,
the higher rate of symptomatic treatment with steroids
could lead to alleviation of some symptoms such as loss of
appetite in comparison to other patient groups [20].
The higher prevalence of social problems that was found
in our study may be related to more advanced disease in
primary brain tumour patients. However, the care for a
loved one who suffers from disorientation and confusion
may also overburden families and raise the need for social
support. This has been identified as a major issue in
families who care for patients with brain tumours, far more
than in the care for the general palliative care population.
Confusion impacts significantly on the social structures, as
it aggravates high levels of distress in family members [9,
21, 22]. This may lead to feelings of stress and problems of
ill health in a majority of primary caretakers [9, 23].
Distress of family members may reflect the increase of
Table 5 Comparison of prevalence of symptoms and other problems with higher intensity (moderate–severe) between the patients with primary
brain tumours, secondary brain tumours and the other patients without malignant brain disease
Group differences
Group Primary brain
tumour (PBT)
N=151
Secondary
brain tumour
(SBT) N=661
Other patients
(OP) N=4872
PBT/SBT PBT/OP SBT/OP
Item
N % N % N %
Physical symptoms
Pain 43 29.5 289 44.1 2,590 53.5 p=0.001 (χ² 10.9) p<0.001 (χ² 33.8) p<0.001 (χ² 20.9)
Nausea 16 10.7 125 19.2 1,350 28 p=0.015 (χ² 5.9) p<0.001 (χ² 21.6) p<0.001 (χ² 22.6)
Vomiting 10 6.7 86 13.3 904 18.7 p=0.027 (χ² 4.9) p<0.001 (χ² 13.9) p=0.001 (χ² 11.6)
Dyspnoea 3 2 191 29.1 1,365 28.3 p<0.001 (χ² 48.4) p<0.001 (χ² 49.7)
Constipation 36 24.7 205 31.7 1,599 33.5 p=0.026 (χ² 4.9)
Weakness 117 80.1 571 87.4 3,981 82.5 p=0.021 (χ² 5.3) p=0.002 (χ² 9.9)
Loss of appetite 62 43.1 408 63.4 3,178 66.6 p<0.001 (χ² 20.1) p<0.001 (χ² 34.4)
Tiredness 98 67.1 470 72.4 3,137 65.2 p<0.001 (χ² 13.3)
Nursing problems
Wound care 24 16.4 135 21.1 986 20.2
Activities of daily living 139 92.7 553 85.1 3,375 70.6 p=0.014 (χ² 6.0) p<0.001 (χ² 34.5) p<0.001 (χ² 59.7)
Psychological problems
Feeling depressed 45 32.1 223 35.1 1,494 31.5
Anxiety 46 32.2 267 41.7 1,765 37 p=0.035 (χ² 4.4) p=0.024 (χ² 5.3)
Emotional strain 54 37.8 297 46.1 1,980 41.5 p=0.027 (χ² 4.9)
Disorientation/confusion 70 50 226 35.1 669 14 p=0.001 (χ² 10.8) p<0.001 (χ² 137.5) p<0.001 (χ² 182.9)
Social problems
Need for social support 84 58.7 343 54.9 2,032 43.2 p<0.001 (χ² 13.5) p<0.001 (χ² 30.2)
Overburden of family 110 74.3 417 65.4 2,405 51.5 p=0.037 (χ² 4.4) p<0.001 (χ² 30.0) p<0.001 (χ² 43.5)
Table 6 Documented neurological problems of patients with primary and secondary brain tumours on admission
Primary brain tumour Secondary brain tumour Other patients
Diagnosis
(ICD)
Reason for admission
(free text)
Diagnosis
(ICD)
Reason for admission
(free text)
Diagnosis
(ICD)
Reason for admission
(free text)
Paresis 34% 2.6% 10.3% 2.1% 2.9% 0.3%
Seizures 18.6% 8.2% 6.1% 3.1% 0.5% 0.1%
Brain oedema 6.2% 5.2% 1.3% 1.7% 0.1% 0.1%
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the uncertainty of the situation [24].
These issues are not merely specific to patients receiving
palliative care and their families, but to the fact that the brain
is affected by a malignant tumour. Therefore, the families_
burden due to the patients' mental impairment and changed
personality must be addressed appropriately already early in
the course of the disease by all disciplines involved, e.g.
neurooncologists, surgeons and radiotherapists.
Compared with patients with primary brain tumours, the
group with secondary brain tumours showed a less reduced
functional status and was assigned to lower levels of
nursing care. Both parameters indicate less advanced
disease than in patients with primary brain tumours, but
still more advanced disease than in the other patients.
Similarly, the differences in symptom scores between
patients with primary brain tumours and other patients
may be related to the general progression of the disease
rather than to the fact that brain metastases have occurred.
By nature of the disease, brain metastases frequently
develop along with metastases at multiple sites as one of
the signs of an overall progression of the disease. This is
supported by the fact that in this group, significantly more
patients died in the period under review.
By analysing the reasons for admission, we also wanted
to explore what the essential needs are that services caring
for these particular patient groups should provide. The
emerging problems that lead to admission reflect some of
the earlier mentioned issues. Although symptom manage-
ment was the leading cause for admission in all groups, it
was far less frequent in patients with primary and secondary
brain malignancies than in other patients. Again, cognitive
changes, functional deficits and social issues were identi-
fied far more commonly as the reason for service
utilisation. Interestingly, even though specific neurological
problems, such as paresis, seizures and brain oedema, were
documented as ICD-diagnoses, they were rarely seen as the
reason for admission by the documenting teams and thus
not perceived as a specific focus for palliative care.
The described specific palliative care needs have to be
taken into account when planning inpatient or outpatient
care for these patient groups, but also for the implementa-
tion of a palliative care approach in neurological and
oncological services.
More specifically, social or psychological support should
be provided early and appropriately for patients with
malignant cerebral involvement and their families to prevent
family members from increasing distress and overburdening.
Therefore,inservicesthatcaretoagreaterextentforpalliative
care patients with central malignancies, multi-professional
structures with a focus on social work and psychology are of
major importance. Offering respite care may be an additional
and reasonable preventative intervention.
This study has some limitations. The categories pre-
sented in the documentation tool were developed with
“general” palliative care patients. Issues specific for patients
with brain tumours may therefore be underrepresented. As
there are still only very few neurologically trained
physicians in palliative care, some neurological problems
may have been overlooked and the data presented may
underestimate the real situation.
Furthermore, the documented symptoms and problems
were assessed by staff and not by the patients themselves.
As many of the documented patients in our study suffered
from cognitive impairment, it may be assumed that the use
of self-assessment would lead to a selection bias in favour
of patients with better cognitive function. Even though
there was no evaluation of the severity of cognitive
impairment beyond staff assessment on a categorical scale,
the routinely performed testing of the cognitive function of
patients with brain malignancies at admission, for example
with the Mini Mental State Examinations, may have
strengthened the results of this study.
Conclusion
This study demonstrates for the first time on a broad,
prospectively collected data pool that palliative care
problems and needs in patients with primary and secondary
brain tumours are significantly different compared with
those of other patients. This information can be used for
designing best possible palliative care. Specific palliative
care problems and reasons for health care utilisation reveal
the need for an appropriate provision of interdisciplinary
and multi-professional care, with a particular view on the
needs of the family caregivers and an early integration of
social and psychological support.
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